Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects.
In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation.
Martin
S
S
Diabetes Research Institute, University of Düsseldorf, FRG.
Schernthaner
G
G
Nerup
J
J
Gries
F A
FA
Koivisto
V A
VA
Dupré
J
J
Standl
E
E
Hamet
P
P
McArthur
R
R
Tan
M H
MH
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D003401:Creatine / Q000097:blood; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007515:Islets of Langerhans / Q000473:pathology / Q000502:physiology; D008297:Male; D011188:Potassium / Q000097:blood; D013997:Time Factors
D003524:Cyclosporins; D006454:Hemoglobins; D003401:Creatine; D011188:Potassium